Unlocking Global Health: How Follow-On Biologics are Set to Enhance Access and Reduce Costs

The Promise of Follow-On Biologics in Global Health

Follow-on biologics, which include biosimilars, biobetters, and bioparallels, offer a pathway to make healthcare more affordable and accessible worldwide. These innovative treatments have the potential to reduce costs while expanding options for patients.

Ivo Abraham, a leading expert at The University of Arizona Cancer Center, recently shared insights at the 2025 Festival of Biologics in San Diego. He highlighted how these therapies can create a fairer healthcare system by making treatments budget-friendly. “Whether it’s a biosimilar, biobetter, or bioparallel, this yields cost efficiencies,” he explained. This means more people can access necessary treatments without overwhelming healthcare budgets.

Abraham delved into the distinctions among these biologics. Biobetters are improved versions of existing molecules, while bioparallels are new drugs that don’t directly reference existing ones. Both aim to compete on cost, providing choices for patients.

The benefits of follow-on biologics go beyond just lowering prices. They can significantly enhance fairness in patient access. Cost-effectiveness studies help demonstrate their positive impact, using metrics like quality-adjusted life years. This is critical for understanding the true value of these treatments.

Real-world data from clinical practices can also strengthen the case for follow-on biologics. Abraham emphasized the need for careful evaluation and risk management. By modeling potential risks—like issues with product interchangeability or supply chain disruptions—healthcare systems can better prepare for changes.

Concerns like natural disasters and trade barriers can impact how these therapies are delivered. Therefore, alternative production and distribution strategies can help minimize risks. Collaborating with international organizations and public-private partnerships can also play a vital role in making follow-on biologics more accessible in lower- and middle-income countries.

Abraham suggests that innovative pricing models and awareness campaigns can bridge gaps in access. This way, more patients around the globe can benefit from these valuable treatment options.

As the world continues to evolve, the conversation around follow-on biologics becomes increasingly important. By focusing on collaboration and creative solutions, we can pave the way for a more equitable health landscape.

For more information on biosimilars and their impact on healthcare access, you can check resources from the FDA.

Source link

Festival of Biologics USA,follow-on biologics,global health care,biosimilars